Vi polysaccharide and conjugated vaccines afford similar early, IgM or IgG-independent control of infection but boosting with conjugated Vi vaccines sustains the efficacy of immune responses.

Vaccination with Vi capsular polysaccharide (Vi-PS) or protein-Vi typhoid conjugate vaccine (TCV) can protect adults against Here, we immunized wild-type (WT) mice and mice deficient in IgG or IgM with Vi-PS or TCVs (Vi conjugated to tetanus toxoid or CRM197) for up to seven months, with and without subsequent challenge with Vi-expressing Therefore, Vi-specific IgM or IgG are independently capable of protecting from infection and any superior protection from vaccination with TCV in adults may relate to responses being able to persist better rather than from differences in the antibody isotypes induced. These findings suggest that enhancing our understanding of how responses to vaccines are maintained may inform on how to maximize protection afforded by conjugate vaccines against encapsulated pathogens such as

Informations de copyright

Copyright © 2023 Jossi, Arcuri, Alshayea, Persaud, Marcial-Juárez, Palmieri, Di Benedetto, Pérez-Toledo, Pillaye, Channell, Schager, Lamerton, Cook, Goodall, Haneda, Bäumler, Jackson-Jones, Toellner, MacLennan, Henderson, Micoli and Cunningham.

Déclaration de conflit d'intérêts

GSK Vaccines Institute for Global Health SRL is an affiliate of GlaxoSmithKline Biologicals SA. FM and RD are employees of the GSK group of companies. SJ and EP participate in a postgraduate studentship program at GSK. MA participated in a postgraduate studentship at GSK at the time of the study. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.